Affymetrix and BioDiscovery Launch a Tailored Copy Number Analysis Software Solution for Cancer Research

By Business Wire,  June 05, 2014, 06:30:00 AM EDT


SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix (Nasdaq:AFFX) and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan® Cytogenetics Suite and OncoScan® FFPE Assay Kit.

"CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of our cancer portfolio," says Dr. Andy Last, Executive Vice President and Chief Operating Officer at Affymetrix. "Researchers have been finding CNVs and copy neutral changes in liquid and solid tumor samples. With the use of Nexus Copy Number, an advanced discovery tool for interrogating large data sets, researchers have been able to identify biomarkers that drive disease progression. The new Nexus Copy Number for Affymetrix software offers researchers a version of the Nexus Copy Number software that is easier to access and has been specifically tailored for Affymetrix' assays."

"We are thrilled to extend our relationship with Affymetrix through this unique product," said Dr. Soheil Shams, BioDiscovery's Chief Scientific Officer. "The high quality data from the Affymetrix assays performs extremely well in our software for detecting copy number variants. We have customers around the world that have been leveraging the CytoScan Cytogenetics Suite and OncoScan platforms for copy number analysis from different types of cancer samples, and we're pleased to be able to offer this joint solution to help scientists to gain further insights into cancer biology."

For product and ordering information on the new Nexus Copy Number for Affymetrix software, contact BioDiscovery, Inc.

PLEASE NOTE:

Affymetrix, the Affymetrix logo, OncoScan, and CytoScan are trademarks of Affymetrix, Inc. All other trademarks and product names are the property of their respective owners.

Affymetrix and BioDiscovery products mentioned in this release are For Research Use Only. Not for use in diagnostic procedures.

About BioDiscovery, Inc.

BioDiscovery Nexus Copy Number software offers simple yet powerful tools for copy number (CNV) and sequence variation analysis and visualization from microarrays and next generation sequencing (NGS), for analysis of complex data such as solid tumor samples and complex constitutional disease. The scientist-driven software embeds powerful statistical tools designed specifically for the end-user, allowing rapid detection of chromosomal aberrations and identification of affected pathways.

BioDiscovery is a leader in the development of breakthrough software and services for advanced copy number variation and expression analysis, enabling customers in drug discovery, research, and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray and next-generation sequencing technologies. For more information about BioDiscovery, please visit www.biodiscovery.com.

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 65,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2013, and other SEC reports for subsequent quarterly periods.

Source: Affymetrix, Inc.



This article appears in: News Headlines

Referenced Stocks: AFFX


Latest News Video

AP Top Stories July 25 A
AP Top Stories July 25 A            




Most Active by Volume

Company Last Sale Change Net / %
FB $ 74.98 3.69 ▲ 5.18%
NOK $ 8.32 0.64 ▲ 8.33%
SIRI $ 3.45 0.01 ▼ 0.29%
YHOO $ 36.17 1.46 ▲ 4.21%
F $ 17.84 0.06 ▲ 0.34%
AAPL $ 97.03 0.16 ▼ 0.16%
BAC $ 15.62 0.10 ▲ 0.64%
T $ 35.50 0.38 ▼ 1.06%

As of 7/24/2014, 04:04 PM